Revolutionizing Multiple Myeloma Treatment: The Rise of Subcutaneous Isatuximab Delivery
For years, intravenous (IV) infusion has been the standard for delivering monoclonal antibodies like isatuximab (Sarclisa) to patients battling multiple myeloma. However, the landscape of treatment is evolving, driven by a desire for greater convenience, improved patient experience, and maintained efficacy. Recent clinical trial data showcases a notable leap forward: subcutaneous (SC) delivery of isatuximab,specifically utilizing a novel on-body injector (OBI) technology.
The challenge with transitioning solid monoclonal antibodies to SC administration lies in their viscosity and volume. Customary manual pushes can be difficult for patients and healthcare providers. Sanofi recognized this and pioneered a solution - the OBI, a small, automated device designed to simplify the process. This device employs a remarkably thin (30 gauge) needle, hidden from view and automatically retracted post-injection, dramatically enhancing safety and ease of use.
The pivotal IRAKLIA study, presented at EHA 2025, confirmed the non-inferiority of the 1400mg flat-dose SC OBI isatuximab compared to IV administration. Crucially, the study met it’s co-primary endpoints: comparable activity (measured by Very Good Partial Remission or better – VGPR rates) and similar pharmacokinetic profiles (assessed by C-trough levels).
Interestingly, the OBI route actually resulted in higher serum isatuximab levels than IV. This is a critical finding, as a flat dose must deliver consistent therapeutic concentrations across a wide range of patient weights. IRAKLIA demonstrated precisely that - maintaining efficacy and safety in patients weighing as little as 40kg and exceeding 100kg.
IRAKLIA paved the way for regulatory approval, but further inquiry was needed to validate the SC OBI approach across all isatuximab-containing regimens. The ISASOCUT study, conducted in France, demonstrated comparable results to established IV regimens when isatuximab was combined with bortezomib – a cornerstone of myeloma treatment. This confirms the potential to broadly implement SC delivery in frontline settings, mirroring the positive outcomes seen in landmark publications in Nature Medicine and The New England Journal of Medicine.
Though, Sanofi didn’t stop there. The ISALCO study directly compared the OBI to manual SC injection. The results were definitive: the OBI device significantly outperformed manual push, solidifying its position as the optimal SC delivery method.
This isn’t simply a shift from IV to SC; it’s a move to the best possible subcutaneous option. The OBI offers a compelling combination of convenience, safety, and efficacy, promising to dramatically improve the quality of life for patients undergoing isatuximab therapy. This innovation represents a significant advancement in multiple myeloma care, empowering patients and streamlining treatment administration.
key Takeaways:
* OBI Technology: A novel on-body injector simplifies subcutaneous isatuximab delivery.
* Non-inferiority Confirmed: IRAKLIA demonstrated SC OBI isatuximab is equivalent to IV in efficacy and safety.
* Broad Applicability: ISASOCUT validates SC OBI use across multiple isatuximab regimens.
* Superior to Manual Push: ISALCO proves the OBI device is more effective than manual subcutaneous injection.
* Improved Patient Experience: The OBI offers convenience, safety, and a potentially better quality of life for patients.